Phase II clinical trial of antineoplastic new drug of Guoding Biotechnology

From left, Liu Shengyong, President of Guoding biotechnology, Wang Jinping, President of Taiwan Legislative Yuan, and Wu Liyu, President of Guoding biotechnology, recently attended few public events, Wang Jinping, President of Taiwan Legislative Yuan On the afternoon of November 26, he appeared at the press conference for launching the phase II clinical trial of new drug of Guoding biotechnology, leading to a lot of turmoil on the scene Ms Wu Liyu, President of Guoding biotechnology, interacted with Wang Jinping She said that three years ago, when Guoding held a press conference on phase I clinical trials of new drugs, Wang Jinping was the guest on the table After three years of human safety and effectiveness tests, androjian has been approved by the US FDA and officially launched phase II clinical trials around the world Wang Jinping can be said to have witnessed the whole process As the founder of Taiwan society legal person National Biotechnology and medical industry promotion association and Taiwan cancer foundation, Wang Jinping has invested a lot of effort in cancer research and praised Guoding's persistence over the years This time, Guoding signed a contract with icon, the world's third-largest clinical research institution, and was assisted by Johns Hopkins University in the United States, a big step forward from its successful listing Liu Shengyong, President of Guoding biotechnology, R & D Party of androjian, and Wei Ming Goh, vice president of the Asia Pacific region of icon, said: "this time, we have officially signed a contract with icon, which is signed by David S Etinger served as the general host of the second phase of the trial plan, which is also an open way to be accountable to the public With more than 10000 employees in 37 countries around the world, icon ranks second in the world in clinical cancer research, with high authority and credibility In this case alone, Guoding has spent 10 million US dollars "Liu Shengyong, chairman of the board of directors, said that due to the unique mechanism of action of androjian, it is expected to improve the current situation that RAS (including KRAS, NRAS, HRAS) gene mutations are not medicable Based on the results of phase II clinical trial, the R & D party will also apply for drug certificate to FDA, hoping to provide more treatment options for patients In addition, except for small cell lung cancer, the R & D side will expand the scope of the test to multiple diseases such as pancreatic cancer, colorectal cancer, blood cancer, lupus erythematosus and hyperlipidemia in the future, hoping to benefit more cancer and chronic patients.